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Ali Akbar MoghadamniaAbstract
Aluminum phosphide (AlP) is a cheap solid fumigant and a highly toxic pesticide which is commonly used for grain
preservation. In Iran it is known as the “rice tablet”. AlP has currently aroused interest with increasing number of
cases in the past four decades due to increased use in agricultural and non-agricultural purposesand also its easy
availability in the markets has increased its misuse to commit suicide. Upon contact with moisture in the
environment, AlP undergoes a chemical reaction yielding phosphine gas, which is the active pesticidal component.
Phosphine inhibits cellular oxygen utilization and can induce lipid peroxidation. It was reported that AlP has a
mortality rate more than 50% of intoxication cases. Poisoning with AlP has usually occurred in attempts to suicide.
It is a more common case in adults rather than teen agers. In some eastern countries it is a very common agent
with rapid action for suicide. Up to date, there is no effective antidote or treatment for its intoxication. Also, some
experimental results suggest that magnesium sulfate, N-acetyl cysteine (NAC), glutathione, vitamin C and E,
beta-carotenes, coconut oil and melatonin may play an important role in reducing the oxidative outcomes of
phosphine. This article reviews the experimental and clinical features of AlP intoxication and tries to suggest a way
to encounter its poisoning.
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Background
Aluminum phosphide (AlP) is a solid fumigant which
has been extensively used since the 1940s. It is easily
available and is purchased in some countries such as
India under trade names e.g. Celphos, Quickphos, Syn-
fume and Phosfume [1]. It has been registered in the
USA and many other countries for the indoor fumiga-
tion of agricultural compounds, animal feeds, processed
foods and also structural as well as outdoor pest control.
In Iran it is known as the rice tablet [2] that can be pur-
chased in local shops.
AlP is a solid pesticide that rapidly became one of the
most commonly used grain fumigants because of its
properties which are considered to be near ideal; it is
toxic to all stages of insects, highly potent, does not
affect seed viability, is free from toxic residues and leaves
little residue on food grains [3]. This highly toxic chem-
ical is cheap and usually formulated in tablets or pellets,
granules and as a dust. Upon contact with moisture in
the environment, it undergoes a chemical reactionCorrespondence: moghadamnia@yahoo.com
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distribution, and reproduction in any mediumyielding phosphine gas, which is the active pesticidal
component [4]. It emerges as a poison of suicidal deaths
as this pesticide has no effective antidote and is freely
available in the market [5].
AlP poisoning is a common mode of suicide in the
agricultural community in northern India [6]. It has cur-
rently aroused interest with increasing number of cases
in the past four decades due to increased use in agricul-
tural and non-agricultural purpose, and also its easy
availability has increased its misuse to commit suicide
[7,8]. Unfortunately, it is rapidly becoming a very com-
monly used agent for self-poisoning in Iran [2,9-11].AlP forms
It is available as tablets (3 g, trade names: Phostoxin,
Bhostoxin, Quickphos Phosphume Phostek) releasing 1 g
PH3 or as pellets (0.6 g, Quickphos, Alphos, Cellphos).
The tablets are green, brown or gray, and each tablet
contains 56% AlP and 44% aluminum carbonate.The chemistry of AlP
The toxic effects of the AlP are due to deadly phosphine
gas liberated when it reacts with water or hydrochloric
acid in the stomach [4]. Phosphine gas (PH3) is thetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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absorbed by inhalation, ingestion, and skin or mucosal
contacts [4]. AlP is available in the forms of tablets or
pellets. It is the active component of the mixture so
aluminum carbonate is added to prevent self-ignition of
phosphine (PH3) which is liberated when AlP comes in
contact with moisture. Each 3 g tablet releases 1 g of
phosphine and so each 0.6 g pellet 0.2 g of phosphine
gas on exposure to moisture and leaves behind a non-
toxic grayish residue of aluminum hydroxide. In addition
to these chemical properties, phosphine may spontan-
eously ignite in the presence of oxygen at concentrations
above a threshold limit range of 0.48-1.9% (v/v) [12].
Phosphine gas is colorless and odorless but in exposure
to air it may give a foul odor (garlicky or decaying fish)
due to the presence of substituted phosphines and
diphosphines [3]. Although exposures to toxicologically
relevant concentrations of phosphine can occur in the
absence of obvious odor detection [4].
Mechanism of action
In the case of oral intake, the phosphine gas released is
absorbed by the gastrointestinal tract with simple diffu-
sion and is mainly excreted by the kidneys and lungs.
Phosphine, like cyanide, inhibits mitochondrial cyto-
chrome oxidase and cellular oxygen utilization [13-15].
Phosphine can inhibit cytochrome C oxidase in vitro
but it has much less activity in vivo [16].
It can rapidly perturb mitochondrial conformation and
inhibit oxidative respiration by 70%. This situation
results a severe decrease in mitochondrial membrane
potential [14].
In presence of AlP cellular superoxide and peroxide
radicals are generated, with subsequent cellular damage
by lipid peroxidation [17-20]. The higher levels of super-
oxide dismuatase (SOD), malonyldialdehyde (MDA) and
catalase in post-mortems suggested their direct relation
to mortality. Decreasing the serum levels of these bio-
chemical parameters to a normal profiles in survivors by
day 5 lead to a restriction of oxidative stress following
phosphine elimination [21]. Some experimental results
suggest that glutathione, melatonin, vitamin C and caro-
tenes play an important role in reducing the effects
caused by oxidative phosphine [8].
The direct toxic effects of phosphine on cardiac myo-
cytes, fluid loss and adrenal gland can induce profound
circulatory collapse [16]. Direct corrosive effects of
phosphides and phosphine on body tissues have been
reported [22].
Toxicity
The fatal dose for a 70 kg adult is 150–500 mg [6,8].
Permissible exposure limit (PET) is 0.3 ppm over an 8 h
shift (for factory stuffs). The range of short termexposure limit (STEL) is 1 ppm and immediate danger
to life and health would be 200 ppm. For lethal dose in
30 min, the range of 400–600 ppm (10 mg/Kg AlP) has
been determined. It has been reported that its LD50
in mice (inhalation of fumes) is 0.68 g/m3 during
65–75 min of exposure and for rats is 1.47 g/m3 dur-
ing 35–50 min of exposure. LD50 for cats is 25 ppm
(2–4 h daily during 3 days) [23].
Etiology
AlP is the most common agent of poisoning in rural or
sub-urban zones of some countries such as India, where
it is usually ingested for suicide [5]. It is also uses as a
suicide agent in Iran [24] but its poisoning in other
countries may be due to occupational exposure [16]. AlP
can induce rarely complications including hepatitis,
acute tubular necrosis, gastroduodentitis, bleeding diath-
esis, corrosive like esophageal stricture and intravascular
hemolysis [25-27].
Epidemiology
An epidemiological study investigated health endpoints
among Indian workers engaged in fumigation of stored
grains [28]. The mean duration of employment among
these workers was 11.1 years, and workplace concentra-
tions of phosphine gas ranged from 0.17 to 2.11 parts
per million (ppm) during the period of investigation. In
this study, workers did not use facemasks, gloves or
aprons as personal protective equipment. The most fre-
quently reported symptoms reported immediately after
completing fumigation activities included headache
(31.8%), dyspnea (31.8%) and chest tightness (27.3%).
Physical examinations of these workers were unremark-
able, and no significant abnormalities were observed in
tests of motor and sensory nerve conduction [28]. Out-
side of the workplace, phosphide fumigants are fre-
quently implicated in association with epidemiological
reports of accidental morbidity and mortality. In a one-
year study period in Allahabad (India) out of a total
13,100 admissions, 301 suspected poisoning cases (2.3%)
of the total admissions were recorded. The prevalence of
AlP poisoning in this period was 11.7% and male to fe-
male ratio was 2:1. Age distribution study showed peak
prevalence in the age group 11–30 years (65.1%)
belonged to the rural area whereas 92 cases (30.6%)
belonged to the urban areas [29].
A three-year (1999–2001) analysis of childhood poi-
sonings in India found that 9% of all cases resulted from
exposure to agricultural pesticides, and AlP fumigants
were the most frequently implicated classification
(29.67% of cases). Most of these cases involved ingestion
pathways of exposure resulting from improper storage of
fumigants [30]. Medical outcomes were not reported in
this study. In another longitudinal, retrospective review
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fumigants were identified as the most commonly impli-
cated poison associated with fatalities (65% of cases)
[31]. In this investigation, the incidence of cases result-
ing in death from the AlP increased during the period of
observation (1972–1997). Morbidity and mortality have
also been reported from phosphine inhalation in asso-
ciation with the in-transit fumigation of ships and rail-
ways [32,33]. In Iran, AlP poisoning has been reported
frequently for suicide attept [34]. Unfortunately, the
mortality rates were reported between 40 to 100%. In a
four-year study period in northern Iran during 1997–
2001, out of 1571 poisoning cases, 33 AlP poisoning
cases (2.1%) were recorded [9] Another study in Gonbad
(Iran), showed that out of 21 AlP poisoning cases, 19
cases have died. The mortality rate in this study was
90.5% [35]. Overall mortality rate of AlP poisoning was
reported 31% in a retrospective 7 years study from
2000–2007 in Tehran [36]. Unpublished data from Babol
town (Iran) showd 25 AlP poisoened cases out of total
1280 cases of poisoning during 2003–2009. In this study,
2 of 25 AlP posoning cases were intoxicated accidentaly
and the others administered AlP for suicide. From nine
cases of death, 7 were female. Age range was 15 to 70
with mean of 27.3. From 25 cases, 6 patients belonged
to the rural area and 18 cases were from the urban sec-
tor. The ratio of male to female was 0.6 [37]. Although
the percentage of poisoning with AlP is low, but the
mortality rate of this kind of intoxication is very high.
The mortality rate of AlP in some studies, were reported
between 37-100% [34,38].
Occupational exposure
Exposure to AlP is a common cause of poisoning from
agricultural pesticide exposures in some parts of the
world [30,31,39].
Chemicals like AlP, having a mortality rate more than
50% are easily available in the markets [40]. The epi-
demiology of occupational and environmental exposure
to phosphine gas in association with phosphide fumi-
gants has been reviewed by the National Institute of Oc-
cupational Safety and Health (NIOSH) [29]. Relevant
findings in a 10-year study of 205 symptomatic expo-
sures included the observation that 75% of cases oc-
curred among individuals who were not directly
handling or applying the fumigants. In 63% of cases
among applicators, and 45% of cases among non-appli-
cators, symptomatic exposure was reported to have oc-
curred from the normal handling of phosphide
fumigants (consistent with the product labeling). In this
case series, approximately 25% of exposures to AlP
among applicators occurred in the context of a misappli-
cation (handling violations) [29]. There were no reported
occupational cases occurring among individuals involvedin the manufacturing process of phosphide fumigants in
this series. A review of an epidemiological report
demonstrates that occupational and environmental ex-
posure to phosphine may also occur from scenarios that
do not involve phosphide fumigants. Case reports of in-
halation exposure to phosphine gas have been described
in association with the clandestine synthesis of metham-
phetamine, as phosphine can be produced from phos-
phorous acid that is formed when iodine and red
phosphorus are combined in aqueous media. Three fa-
talities have been reported from acute inhalation of
phosphine gas, which occurred in a motel room where
methamphetamine was being synthesized [41]. The
other study described a case of transient symptoms of
dizziness, headache, cough and diarrhea in a law en-
forcement official who was investigating a clandestine
methamphetamine laboratory [42]. In this case, the
affected individual was exposed to phosphine gas at a
concentration of 2.7 ppb for 20–30 min [4].
Clinical manifestations
Vomiting, abdominal pain, loose motions, restlessness
have been observed. Cardiovascular complications in-
clude thread pulse, tachycardia, tachypnoea, acidosis,
marked hypotension, palpitation, and unresponsive
shock to conventional treatment. Patients remain men-
tally clear till cerebral anoxia due to shock supervenes
resulting in drowsiness, delirium and coma [28]. Some
common complications of AlP poisoning include
hemorrhage, acute renal failure, disseminated intravas-
cular coagulation and arrhythmias. Several ECG changes
ranging from ST segment elevation/depression, PR and
QRS interval prolongation, complete heart block to ec-
topic pace making and also fibrillation have been
reported following ALP poisoning. Reversible myocardial
injury has been described as well [28]. In the case of AlP
poisoning patients can present anteroinferior wall is-
chaemia with incomplete right bundle branch block
(RBBB) which is progressed to idioventricular rhythm,
complete RBBB, and T-wave flattening simulating myo-
cardial ischaemia. These changes were due to toxic in-
jury to myocardium [43].
Pulmonary edema, dyspnoea, cyanosis, & altered sen-
sorium may be discovered in AlP poisoning. Other rare
effects include hepatitis, disseminated intravascular co-
agulation, and acute tubular necrosis. The complications
noticed are pericarditis, congestive cardiac failure, acute




Diagnosis is made by laboratory and clinical tests. The
factors of positive history of ingestion, symptoms
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phosphine positive in gastric aspirate and breath alone
or in combination would help the diagnosis. The breath
of AlP intoxicated patients has a garlic-like odor. The
plan of diagnosis is based on the patient’s history and
a positive result (blackening) on tests of the patient's
breath with paper moistened with fresh silver nitrate
solution due to exhalation of PH3 or by biochemical
analysis of blood or gastric aspirate for phosphine
[45-47].
Using filters impregnated with silver nitrate [48] and
ion chromatographic methods [49] were recruited to de-
termine phosphine in the bio-samples. Gas chromato-
graphic procedure in survivors [50-52] and post-mortem
specimens [53] has been developed for the measurement
of phosphine levels.
Gas chromatographic technique using a nitrogen
phosphorus detector has been introduced for phosphine
measurement in post mortem stomach contents, blood,
and liver specimens [54].
Laboratory assessment is mainly done to obtain the prog-
nosis. Leucopenia indicates severe AlP toxicity. Increased
serum glutamic oxaloacetic transaminase (SGOT) or
serum glutamic pyruvic transaminase (SGPT) and induced
metabolic acidosis indicate moderate to severe AlP over-
dose. Decreased plasma magnesium level has been
reported while potassium might have been increased or
decreased [55]. Plasma raised level of renin is significant
as its level has a direct relationship with mortality and
proportion to the dose of AlP. The serum level of corti-
sol is usually decreased in severe AlP poisoning [56].
It has been demonstrated that AlP can induce hepato-
toxicity. The main findings were sinosoid conjestion,
fatty liver changes, central vein conjestion, destruction
of neucleos of hepatocytes and centrilubolar necrosis.
Manifestations of hepatotoxicity usually develop 72
hours after AlP intoxication. Death due to acute hepato-
cellular toxicity and fulminant hepatic failure has also
been reported in acute intoxication.
Cardiovascular and respiratory system changes can
also lead to death [16,57]. In myocardial tissue, AlP
induces conjestion, necrosis and leucocytes infiltration
[38]. ECG shows various manifestations such as ST de-
pression or elevation, bundle branch block, ventricular
tachycardia, ventricular fibrillation [28,58-60]. Wall mo-
tion abnormalities, decreased ejection fraction, general-
ized hypokinesia of the left ventricle, and pericardial
effusion can be seen in echocardiography [61].
Edema, congestion, hemorrhage, athlectasia, capilary
vasodialation and alveolar wall thikening were the most
pulmonary complications of AlP intoxication [38]. Chest
X-ray may represent hilar or perihilar congestion, when
ARDS occurs [58].Patients may demonstrate hyperglycemia and metheo-
moglubinemia [24,62]. Development of refractory shock,
ARDS, aspiration pneumonitis, anaemia, metabolic acid-
osis, electrolyte imbalance, coma, severe hypoxia, gastro-
intestinal bleeding, and pericarditis may be observed
following acute AlP poisoning but these manifestations
are associated with poor prognosis. The outcome of in-
toxication correlates best with the number of vomiting
the patient gets after ingestion and the severity of
hypotension the patient develops [44].
Simplified Acute Physiology Score II (SAPSII) was pro-
posed to better estimating the outcome of paitients with
acute AlP poisoning requiring ICU admission. Based on
a study, SAPSII calculated within the first 24 hours was
recognized as a good prognostic indicator [63].
Postmortem findings
Biochemical and histopathological findings in post-
mortem cases revealing pulmonary oedema, asphyxic
lesions in the pulmonary parenchyma, gastrointestinal
mucosal congestion, and petechial haemorrhages on the
surface of liver and brain. Desquamation of the lining
epithelium of the bronchioles, vacuolar degeneration of
hepatocytes, dilatation and engorgement of hepatic cen-
tral veins, sinusoids and areas showing nuclear fragmen-
tation [64,65].
Experimental study
Many studies were done to obtain possible antidote or
treatment of AlP intoxication [44,66-68]. Magnesium
content is decreased by AlP poisoning and it is believed
that to compensate the magnesium levels can deteriorate
the AlP poisoning outcomes [67,69]. AlP poisoning was
intensity induced in mice to achieve an antidote [34]. In
that study, male albino mice were intoxicated by AlP
(10, 20 and 40 mg/kg) and its LD50, histopathological
effects on heart, lung, kidney and liver were studied. The
dose 40 mg/kg of AlP was considered as the LD50. The
mice that were exposed to this dose died during
35 ± 15 min. Pathologic findings showed common
microscopic changes in the liver. Trying to achieve an
antidote, showed that also pretreatment of sodium selen-
ite has not affected mortality latency, but it decreased
the pulmonary and hepatic complications (Table 1).
This result is consistent with previous studies [70,71].
N-acetyl systeine (NAC) in dose 50–100 mg/kg also
improved the hepatic manifestations and prevented
hepatic necrosis. This finding is in agreement to some
other investigations [28,72]. The NAC also delayed the
mortality latency time up to 138 ± 13 min. Vitamin C
(500–1000 mg/kg) delayed mortality latency time up to
250 ± 70 min. Based on this study pretreatment of so-
dium selenite does not improve the mortality rate except




Delayed time to death
before treatment
Delayed time to death
after treatment
P value 95% CI
AlP (40 mg/kg of mice) + saline 35 ± 15 39 ± 14 NS -
AlP + sodium selenite (3 mg/kg) 42 ± 12 45 ± 16 NS -
AlP + NAC (50 mg/kg) 45 ± 20 138 ± 13 0.0001 -37.3 , - 92.19
AlP + Vitamin C (500mg/kg) 46 ± 12 250 ± 17 0.0005 -38.1, -367.9
AlP: Aluminum phosphide; NAC: N-acetyl cysteine; NS: none significant by t-student test.
Reproduced from Moghadamnia, A.A., et al., Aluminum phosphide poisoning in mice and the procedure for its management. J Babol Univ Med Sci . 2000.
2(4): p. 25-33.
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ity latency time and can prevent hepatic complications
[34]. It is suggested that the NAC can be administered
as an effective treatment in AlP poisoned patients. Since
sodium selenite can inhibit free radicals production and
prevent oxidative stress [73-75], should be considered as
a possible treatment in the case of AlP poisoning.
Role of exposure route
The presenting symptoms depend on the route of ad-
ministration. Poisoning by inhalation produces irritation
of the mucous membrane, dizziness, easy fatigability,
nausea, vomiting, headache and diarrhea in mild expos-
ure. Ataxia, numbness, paraesthesia, muscle weakness,
paralysis, diplopia and jaundice result from a moderate
degree of exposure. In severe cases of inhalational poi-
soning, the patient presents with acute respiratory dis-
tress syndrome (ARDS), congestive cardiac failure,
convulsion and coma. Nausea, vomiting and abdominal
pain are the earliest symptoms that appear after inges-
tion. Gastrointestinal manifestations which present in
moderate to severe intoxication are abdominal pain, epi-
gastric tenderness and excessive thirst while cardiovas-
cular abnormalities seen are profound hypotension, dry
pericarditis, myocarditis, acute congestive heart failure
and arrhythmias. Involvement of the respiratory system
may lead to dyspnoea, which may progress to Type I or
II respiratory failure. Nervous system manifestations in-
clude headache, dizziness, altered mental status, convul-
sion, acute hypoxic encephalopathy and coma. Renal
and hepatic failures are the other manifestations. Some
rare findings in AlP poisoning are muscular weakness,
wasting, tenderness in proximal lower limb muscles,
bleeding diathesis due to capillary damage, acute adreno-
cortical insufficiency and the pseudoshock syndrome
due to impaired fluid distribution which results in
micro-circulatory failure [76].
Mortality
The specified fatal dose of AlP is 0.15-0.5 g. However,
most of the patients present with ingestion of three or
more tablets which invariably results in death [3]. Theaverage time interval between ingestion of AlP and death
is three hours (1–48 hours), 95% of the patients die
within 24 hours and the commonest cause of death in
this group is cardiac dysrhythmia. Severity of poisoning
depends upon type of compound consumed. Fresh and
active compounds (tablets) commonly affect heart,
lungs, GI tract and kidneys; causing severe metabolic
acidosis and high mortality. Broken or granular forms of
tablets cause mild hypotension and ECG changes; mild
metabolic acidosis and low mortality as activity of com-
pound is less. Powder form of tablets is inactive; cause
no systemic effects & no mortality [77]. Death after 24
hours is usually due to shock, acidosis, ARDS and car-
diac dysrhythmia. Mortality depends upon dose of poi-
son, severity of poisoning, duration of shock, failure of
response of shock to resuscitative measures & severity of
hypomagnesaemia [78]. Non-survivors have more severe
hypotension and metabolic acidosis than the survivors
who have more severe vomiting [44]. The mortality rate
is highly variable, ranging from 37-100% and can reach




Managing AlP poisoning, should be started as soon as
possible. For confirmatory diagnosis getting history and
clinical examination should not be delayed [79]. To re-
duce the absorption of phosphine gastric lavage with po-
tassium permanganate (1:10,000) is done. Potassium
permanganate (1:10000) is used as it oxidizes PH3 to
form non-toxic phosphate. This is followed by slurry of
activated charcoal (approximately 100 g) given through a
nasogastric tube. Some cathartic (liquid paraffin) is given
to accelerate the excretion of AlP and phosphine. Anta-
cids and proton pump blockers are added for symptom-
atic relief [61,76]. Correction of plasma glucose level can
help the patient to get better [24,79,80].
The most important factor for success is resuscitation
of shock and institution of supportive measures as soon
as the patient’s arrival. IV line should be established and
2–3 liters of normal saline should be given within the
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and pulmonary capillary wedge pressure (PCWP). The
aim is to keep the CVP at around 12–14 cm of water
[81]. Some reports have recommended rapid infusion of
saline (3–6 liters) in the initial 3 hr. 24 Low dose dopa-
mine (4–6 μg/kg/min) is given to keep systolic blood
pressure >90 mm Hg. Hydrocortisone 200–400 mg every
4–6 h is given intravenously to combat shock, reduce
the dose of dopamine, check capillary leakage in lungs
(ARDS) and to potentiate the responsiveness of the body
to endogenous and exogenous atecholamines [10-12].
Oxygen is given for hypoxia. ARDS requires intensive
care monitoring and mechanical ventilation. Phosphine
excretion can be increased by maintaining adequate
hydration and renal perfusion with intravenous fluids
and low dose dopamine (4–6 μg/kg/min). Diuretics like
furosemide can be given if systolic blood pressure is
>90 mm Hg to enhance excretion as the main route of
elimination of phosphine is renal [82]. All types of ven-
tricular arrhythmias are seen in these patients and
the management is the same as for arrhythmias in other
situations [82]. Bicarbonate level less than 15 mEq/L
requires sodabicarb in a dose of 50–100 mEq intraven-
ously every 8 hour till the bicarbonate level rises to
18–20 mEq/L. Patients may require up to 300–500 ml of
sodium bicarbonate [59]. Dialysis may be required for
severe acidosis and acute renal failure [3].
Specific therapy
The clinical management of intoxication from AlP is
mainly supportive. The administration of H2 receptor
antagonists has been recommended after AlP ingestion
to reduce the gastric acidity and prevent further liber-
ation of phosphine gas. Hypo-magnesemia is a common
outcome of acute poisoning of phosphine gas exposure
[66] and intracellular magnesium plays an important
role as a co-factor in the synthesis and activity of gluta-
thione and other antioxidants, the administration of
intravenous magnesium has been investigated in cases
of AlP poisoning. In a trial of 50 patients, individuals
receiving repeated doses of intravenous magnesium had
significant improvement in indicators of oxidative stress
and a lower incidence of mortality (20%) in comparison
to control subjects (44% mortality) [74]. Oral adminis-
tration of the anti-ischemic drug trimetazidine, which
works through a metabolic mechanism of decreasing the
production of oxygen-derived free radicals and stimulat-
ing the oxidative metabolism of glucose [83,84] has been
suggested. It was temporally associated with clinical
improvement in a case report of occupational inhalation
exposure to phosphine gas from AlP [85]. Magnesium
sulphate use (both high and low dose) did not improve
survival in controlled clinical trials. Hence using it is not
recommended [86]. Administration of sorbitol solution(at a dose of 1-2 ml/kg) as a cathartic and vegetable oils
and liquid paraffin as inhibitor of phosphine release
from the overdosed AlP has been suggested [87]. It was
reported that coconut oil has a role in managing acute
AlP poisoning even 6 h post ingestion [80]. Digoxin has
been suggested for treatment of cardiogenic shock
induced by acute AlP intoxication [88].
Conclusion
Exposure to phosphine gas released from ALP fumigants
increases risks of major morbidity and mortality. There
is an increasing need for improved knowledge of these
risks with an emphasis on recognition, management and
prevention. The fast progression to life-threatening
symptoms, ineffective therapeutic ways to solve its in-
toxication and limited data on the efficacy of therapeutic
interventions pose challenges to the clinicians and emer-
gency staffs. People handling this fumigant must be
aware of its lethal aspects. They should be prohibited
from keeping and using this poison at the home. They
should be advised to cover the tablets in open fields after
use. They should keep their tablets away from the reach
of children and other family members. Official health
care system should restrict the open sales of this pesti-
cide. Vendors and shop keepers should not sell the
tablets to young people and children without proper
verification and confirmation. Dealers not following the
health system instructions should be punished. The
manufacturers better be advised to make small packs of
2 – 3 tablets with suitable container. If possible all of the
phosphide derivatives compounds should be forbidden
forever for everyone.
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